Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low molecular weight heparins: are they different?

J Fareed1, D Hoppensteadt, W Jeske

  • 1Department of Pathology and Pharmacology, Loyola University Medical Center, Maywood, Illinois, USA. JFareed@luc.edu

The Canadian Journal of Cardiology
|October 21, 1998
PubMed
Summary

Low molecular weight heparins (LMWHs) show distinct antithrombotic effects influenced by manufacturing. Product-specific TFPI release and dose-dependent actions are key to their efficacy and varied hemorrhagic responses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regional and Systemic Prothrombotic Biomarkers in Varicose Vein Patients and Healthy Controls.

Journal of vascular surgery. Venous and lymphatic disorders·2016
Same author

Blood Sampled Directly from Varicose Veins Reveals Activation of Inflammatory Processes.

Journal of vascular surgery. Venous and lymphatic disorders·2016
Same author

Do blood constituents in varicose veins differ from the systemic blood constituents?

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2015
Same author

Elevated endocan levels and its association with clinical severity in Stevens-Johnson Syndrome and toxic epidermal necrolysis.

International angiology : a journal of the International Union of Angiology·2014
Same author

Pharmacological profile of sulodexide.

International angiology : a journal of the International Union of Angiology·2014
Same author

Medical management of patients with peripheral arterial disease.

International angiology : a journal of the International Union of Angiology·2014

Area of Science:

  • Pharmacology
  • Biochemistry
  • Thrombosis Research

Background:

  • Low molecular weight heparins (LMWHs) are used for deep vein thrombosis (DVT) prophylaxis and are explored for cardiovascular/cerebrovascular uses.
  • Manufacturing variations create distinct pharmacological and biochemical profiles for each LMWH, impacting clinical performance.
  • LMWH specific activities range from 35-45 anti-IIa U/mg to 80-120 anti-Xa U/mg.

Purpose of the Study:

  • To investigate the product-specific antithrombotic and anticoagulant effects of LMWHs.
  • To explore the role of tissue factor pathway inhibitor (TFPI) release in LMWH action.
  • To assess the impact of repeated LMWH administration on antithrombotic and hemorrhagic effects.

Main Methods:

  • Evaluation of LMWH specific activity in anticoagulant assays.

Related Experiment Videos

  • Assessment of dose- and time-dependent antithrombotic effects in animal models.
  • Measurement of ex vivo anticoagulant actions and TFPI release after administration in animal and primate models.
  • Analysis of repeated LMWH administration effects, mimicking DVT prophylaxis.

    • Main Results:

    • LMWHs demonstrate product-specific dose- and time-dependent antithrombotic effects in animal models.
    • Sustained antithrombotic effects can occur without detectable ex vivo anticoagulant actions.
    • LMWHs induce TFPI release, which is relevant to their actions and varies by product.
    • Repeated LMWH administration enhances antithrombotic effects, but hemorrhagic responses are product-dependent.

    Conclusions:

    • LMWH efficacy and safety are significantly influenced by product-specific characteristics.
    • TFPI release is a key mechanism underlying LMWH's antithrombotic effects.
    • Understanding product-specific profiles is crucial for optimizing LMWH use in prophylaxis and treatment.